TREATMENT OF B-CELL LYMPHOMA WITH MONOCLONAL ANTI-IDIOTYPE ANTIBODY
TREATMENT OF B-CELL LYMPHOMA WITH MONOCLONAL ANTI-IDIOTYPE ANTIBODY
复制标题
DOI：
10.1056/nejm198203043060906
复制
发表时间：
1982-01-01
影响因子：
158.5
通讯作者：
LEVY, R
中科院分区：
文献类型：
--
作者：
MILLER, RA;MALONEY, DG;LEVY, R
人类B细胞恶性肿瘤是由表达正常B淋巴细胞特征性表面标志物的细胞的单个克隆增殖引起的。1，2特别是，这些细胞表达的表面免疫球蛋白是单克隆的-即，限制于单个轻链类型和对每种情况独特的特定可变区。每个淋巴瘤克隆的独特免疫球蛋白可变区（独特型）可以被认为是肿瘤特异性标志物，将患者的肿瘤细胞与正常细胞区分开来。我们和其他人已经证明，抗独特型抗体可用于监测B细胞肿瘤，并研究这些肿瘤的生物学。
HUMAN B-cell malignant tumors result from the proliferation of single clones of cells that express surface markers characteristic of normal B lymphocytes.1,2In particular, the surface immunoglobulin expressed by these cells is monoclonal — i.e., restricted to a single light-chain type and to a particular variable region unique to each case. The unique immunoglobulin variable region (idiotype) of each lymphoma clone may be considered a tumor-specific marker, distinguishing tumor cells from normal cells in the patient. We and others have shown that anti-idiotype antibodies can be used to monitor B-cell tumors and to investigate the biology of these tumors.345Because . . .